Agilent Technologies agreed to acquire Biocare Medical for $950 million in cash to broaden its pathology portfolio with immunohistochemistry (IHC), in situ hybridization (ISH), FISH assays and more than 300 specialized antibodies. Agilent said the deal strengthens its diagnostic reagents and automated staining offerings and expands addressable markets across clinical pathology labs and research customers. The transaction is positioned as a strategic complement to Agilent’s existing instrumentation and consumables, enabling integrated pathology workflows. Agilent cited expected revenue synergies from cross‑selling and a stronger foothold in the fast‑growing molecular pathology segment. Regulatory approvals and customary closing conditions remain; Agilent plans to integrate Biocare into its pathology business and scale commercial deployment globally.